Clinical Trial Record

Return to Clinical Trials

A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies


2020-03-15


2021-07-15


2022-04-15


126

Study Overview

A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies

A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.

Patients will be randomized in a 2:1 ratio. Patients in the experimental arm will receive automatically generated personalized educational videos (PEV) and questionnaires regarding side effects and quality of life (QOL) to either their cell phone or email. The videos will be personalized to each patient based on their demographics, specific medical instructions and treatment plan. Data collected regarding side effects and QOL in the experimental arm will be used in order to facilitate real time intervention through real time provider alert system. A link to the first PEV will be sent before the first chemotherapy cycle, addressing the diagnosis and type of malignancy, chemotherapy protocol, common side effects and their management. Side effects questionnaire will be sent every week while QOL questionnaire will be sent every 6 weeks. Patients will be followed from recruitment through three weeks after completion of the planned treatment protocol. If treatment is discontinued prior to completion of the protocol, follow-up will end three weeks after the last administered treatment.

  • Colon Cancer
  • Gastric Cancer
  • Pancreas Cancer
  • Rectal Cancer
  • Cholangiocarcinoma
  • Small Bowel Cancer
  • Esophageal Cancer
  • OTHER: patient engagement platform
  • SHEBA-19-6013-YL-CTIL

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2020-02-23  

N/A  

2022-04-21  

2020-03-19  

N/A  

2022-04-28  

2020-03-20  

N/A  

2020-03  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Health Services Research


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: personalized engagement platform

Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects.

OTHER: patient engagement platform

  • 1. Allows patients to receive the action plan as educational videos on demand. 2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan.
NO_INTERVENTION: control group

The control group will not be registered to the PEP nor receive any PEVs.

Primary Outcome MeasuresMeasure DescriptionTime Frame
Feasibility of PEP (percent of patients using videos/complete questionnaires)To assess the feasibility of implementing a PEP in the outpatient gastrointestinal malignancies service, at Sheba Medical Center, for patients undergoing active chemotherapy treatment. This outcome will be measured as percent of patients using the videos and percent of patients that complete the questionnaires.3 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Secondary clinical outcomes 1 (mean number of referrals)To monitor mean number of referrals to emergency room and admissions to the inpatient department.3 years
Secondary clinical outcomes 2 (level of chemotoxicity)To measure level of chemotoxicity - Neuropathy, diarrhea, nausea and vomiting, stomatitis and fever; using total number and percent of patients with side effects in each arm and Common Terminology Criteria for side effects (CTCAE) grading scale.3 years
Secondary clinical outcomes 3 (Quality of Life)To measure patient assessment of Quality of Life (QoL) using a validated questionnaire (QLQ-C30).3 years
Secondary clinical outcomes 4 (treatment intensity and continuity)To evaluate treatment intensity and continuity measured as number of chemotherapy cycles and cumulative chemotherapy dose.3 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Individuals with a newly diagnosed gastrointestinal malignancy, treated at the outpatient clinic of the Institute of Oncology at the Sheba Medical Center 2. Individuals planned to receive one of the following cytotoxic chemotherapy protocols:
    1. FOLFOX - a combination of 5-fluoruracil, leucovorin and oxaliplatin. 2. FOLFOIRI - a combination of 5-fluoruracil, leucovorin and irinotecan. 3. FOLFIRINOX - a combination of 5-fluoruracil, leucovorin, oxaliplatin and irinotecan. 4. De Gramont - 5-fluoruracil and leucovorin. 3. Ability to read and comprehend Hebrew language text. 4. Ability to see computer or cell phone screen (i.e., no visual impairment).
    Exclusion Criteria:
    1. Eastern Conference Oncology Group (ECOG) performance status greater than 2. 2. Cognitive deficits that would preclude understanding of consent form and/or questionnaires. 3. Inability to read and comprehend Hebrew language text. 4. Current participation in a therapeutic clinical trial.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Ofer Margali, MD PhD, Sheba Medical Center

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available